NCT04123366 2026-04-22
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07382544 2026-02-25
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT00777582 2026-01-13
Phase I Comparative Bioavailability Study
AstraZeneca
Phase 1 Active not recruiting
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05522491 2025-12-11
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting